Shares of Werewolf Therapeutics (NASDAQ:HOWL) more than doubled on Friday after the company announced a definitive merger agreement with privately-held Ambros Therapeutics. The stock closed the session at $0.8735, up 102.6%, on extraordinary volume of 290.4 million shares—nearly 197 times its three-month average daily turnover.
The dramatic rally, however, masks a fundamental dilution for legacy Werewolf investors. Under the terms of the all-share transaction, existing Werewolf shareholders are expected to own just 6.8% of the combined company. Ambros shareholders will hold approximately 71.7%, with PIPE investors taking 21.5%. The ownership split reflects the relative valuations: Ambros is valued at $500 million pre-financing, while Werewolf is assigned a $47.5 million valuation.
The merger will be accompanied by a $150 million private investment in public equity (PIPE) led by RA Capital Management and Janus Henderson Investors. These funds are earmarked to advance Ambros's lead asset, neridronate, through its pivotal Phase 3 CRPS-RISE trial in warm complex regional pain syndrome type 1 (CRPS-1). Topline results are expected in 2028, and the company says it expects to be fully funded through that milestone.
Friday's market capitalization of $42.5 million was 10.6% below Werewolf's agreed pre-financing valuation, reflecting the market's read on the deal's terms. The stock touched an intraday high of $1.05 but closed 16.8% off that peak, suggesting some investors took profits after the initial surge. The wide trading range underscores the volatility inherent in biotech merger arbitrage situations.
The combined company will operate under the Ambros Therapeutics name and list on Nasdaq under the ticker AMBX. Its headquarters will relocate to San Diego. The transaction is expected to close in the first quarter of 2027, subject to shareholder approval, a valid registration statement, and Nasdaq clearance.
Neridronate, a bisphosphonate, has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA. If approved, it could become the first FDA-approved treatment for warm CRPS-1, which affects an estimated 65,000 new patients annually in the U.S. However, these designations do not guarantee approval, and a failed Phase 3 trial would significantly impair the combined entity's value.
For legacy Werewolf shareholders, the deal also includes a contingent value right (CVR) tied to proceeds from the sale of certain INDUCER and INDUKINE technology assets to EMD Serono. That transaction, announced earlier in August, provided an upfront payment of $28 million with an additional $5 million due upon completion of the technology transfer. Werewolf also reported $22.0 million in cash as of June 30, but had previously flagged substantial doubt about its ability to continue as a going concern over the next 12 months.
The company's strategic review had led to significant cost reductions, with second-quarter research and development expenses falling to $6.2 million from $13.1 million a year earlier. General and administrative costs, however, rose to $7.7 million from $4.4 million during the same period, reflecting the strategic review process.
Analyst coverage prior to the merger was limited. As of August 5, a consensus of seven analysts rated the stock a Hold with an average price target of $3.75, but those ratings addressed the legacy Werewolf business and are now largely obsolete. Investors should await new coverage that reflects the combined entity's prospects.
Key risks remain: the merger could fail to close or close on different terms, the final ownership percentage depends on Werewolf's net cash at closing, and neridronate's regulatory path is uncertain. The registration statement and an updated net cash estimate will provide further clarity. Friday's rally narrowed the gap to the agreed valuation, but the stock's future will hinge on the successful execution of the merger and the progress of the CRPS-RISE trial.
